Jacobs Levy Equity Management Inc. Invests $1.92 Million in Caribou Biosciences, Inc. (NASDAQ:CRBU)

Jacobs Levy Equity Management Inc. acquired a new stake in Caribou Biosciences, Inc. (NASDAQ:CRBU - Free Report) during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 1,208,069 shares of the company's stock, valued at approximately $1,921,000. Jacobs Levy Equity Management Inc. owned approximately 1.33% of Caribou Biosciences as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the stock. JPMorgan Chase & Co. grew its position in shares of Caribou Biosciences by 475.9% in the fourth quarter. JPMorgan Chase & Co. now owns 2,495,922 shares of the company's stock valued at $3,969,000 after purchasing an additional 2,062,563 shares during the last quarter. Barclays PLC grew its holdings in Caribou Biosciences by 12.0% in the 4th quarter. Barclays PLC now owns 145,417 shares of the company's stock valued at $231,000 after buying an additional 15,578 shares during the last quarter. Sei Investments Co. bought a new position in Caribou Biosciences in the 4th quarter worth approximately $102,000. US Bancorp DE lifted its holdings in shares of Caribou Biosciences by 3,524.2% during the fourth quarter. US Bancorp DE now owns 27,218 shares of the company's stock worth $43,000 after buying an additional 26,467 shares during the last quarter. Finally, American Century Companies Inc. boosted its position in shares of Caribou Biosciences by 9.2% in the fourth quarter. American Century Companies Inc. now owns 159,822 shares of the company's stock valued at $254,000 after acquiring an additional 13,421 shares during the period. 77.51% of the stock is currently owned by institutional investors and hedge funds.

Caribou Biosciences Trading Down 5.0%

CRBU stock traded down $0.06 during trading on Wednesday, reaching $1.05. 228,651 shares of the stock were exchanged, compared to its average volume of 1,483,106. Caribou Biosciences, Inc. has a twelve month low of $0.66 and a twelve month high of $3.19. The company has a market capitalization of $97.19 million, a P/E ratio of -0.63 and a beta of 2.36. The stock has a 50 day simple moving average of $0.86 and a 200-day simple moving average of $1.41.

Caribou Biosciences (NASDAQ:CRBU - Get Free Report) last announced its quarterly earnings data on Thursday, May 8th. The company reported ($0.43) EPS for the quarter, hitting analysts' consensus estimates of ($0.43). The company had revenue of $2.35 million during the quarter, compared to the consensus estimate of $1.48 million. Caribou Biosciences had a negative return on equity of 45.46% and a negative net margin of 1,290.81%. Equities analysts predict that Caribou Biosciences, Inc. will post -1.64 EPS for the current year.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reaffirmed a "buy" rating and set a $3.00 target price (down previously from $9.00) on shares of Caribou Biosciences in a research report on Monday, April 28th. Four investment analysts have rated the stock with a buy rating, According to data from MarketBeat, Caribou Biosciences presently has a consensus rating of "Buy" and a consensus target price of $7.40.

About Caribou Biosciences

Caribou Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma.